Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS®
(Brentuximab Vedotin) in Mycosis Fungoides
-Designation Supports Regulatory Strategy for ADCETRIS in CTCL, including
Ongoing Phase III ALCANZA Trial-
-Investigator Data on ADCETRIS in CTCL to be Presented at Upcoming ASH Annual
BOTHELL, Wash. -- November 26, 2012
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that ADCETRIS
(brentuximab vedotin) has been granted orphan drug designation by the U.S.
Food and Drug Administration (FDA) for the treatment of mycosis fungoides
(MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle
Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology
Company, are conducting the ALCANZA trial, a phase III clinical trial of
ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS
is not approved for the treatment of CTCL.
“This orphan drug designation is a part of our ADCETRIS regulatory strategy,
designed to complement the Special Protocol Assessment for the ongoing ALCANZA
study,” said Clay B. Siegall, President and Chief Executive Officer of Seattle
Genetics. “The encouraging data from investigator-sponsored trials of ADCETRIS
in CTCL, which will be presented at ASH, provide further support for our
activities in this patient population.”
FDA orphan drug designation is intended to encourage companies to develop
therapies for the treatment of diseases that affect fewer than 200,000
individuals in the United States. This designation provides Seattle Genetics
with the opportunity for seven years of marketing exclusivity, grant funding
to defray costs of clinical trial expenses, tax credits for clinical research
expenses and potential waiver of the FDA's application user fee.
The ALCANZA trial is a randomized phase III clinical trial of ADCETRIS for
relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus
investigator’s choice of methotrexate or bexarotene in patients with
CD30-positive CTCL, including those with primary cutaneous anaplastic large
cell lymphoma (pcALCL) or MF. The primary endpoint of the study is overall
response rate lasting at least 4 months. Approximately 124 patients will be
enrolled in the pivotal trial. The ALCANZA trial is being conducted under a
Special Protocol Assessment agreement from the FDA. The study also received
European Medicines Agency scientific advice. For more information about the
ALCANZA trial, visit www.clinicaltrials.gov.
At the 54^th American Society of Hematology (ASH) Annual Meeting and
Exposition being held December 8-11, 2012 in Atlanta, GA, data from two
investigator-sponsored trials of ADCETRIS in CTCL will be reported:
Brentuximab vedotin demonstrates significant clinical activity in relapsed or
refractory mycosis fungoides with variable CD30 expression (Abstract #797)
*Oral presentation on Monday, December 10; 7:15 p.m. Eastern Time (ET) in
*First author: Dr. Michael Krathen, Stanford University, Stanford, CA
Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30-positive
cutaneous T-cell lymphomas and lymphoproliferative disorders (Abstract #3688)
*Poster presentation on Monday, December 10; 6:00 p.m. to 8:00 p.m. ET in
*First author: Dr. Madeleine Duvic, The University of Texas MD Anderson
Cancer Center, Houston, TX
ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal
antibody attached by a protease-cleavable linker to a microtubule disrupting
agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary
technology. The ADC employs a linker system that is designed to be stable in
the bloodstream but to release MMAE upon internalization into CD30-expressing
ADCETRIS was granted accelerated approval by the FDA in August 2011 for two
indications: (1) the treatment of patients with Hodgkin lymphoma after failure
of autologous stem cell transplant (ASCT) or after failure of at least two
prior multi-agent chemotherapy regimens in patients who are not ASCT
candidates, and (2) the treatment of patients with systemic anaplastic large
cell lymphoma (sALCL) after failure of at least one prior multi-agent
chemotherapy regimen. The indications for ADCETRIS are based on response rate.
There are no data available demonstrating improvement in patient-reported
outcomes or survival with ADCETRIS.
ADCETRIS was granted conditional marketing authorization by the European
Commission in October 2012 for two indications: (1) the treatment of patients
with Hodgkin lymphoma after failure of ASCT or after failure of at least two
prior multi-agent chemotherapy regimens in patients who are not ASCT
candidates, and (2) the treatment of patients with sALCL after failure of at
least one prior multi-agent chemotherapy regimen. See important safety
Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the
terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian
commercialization rights and the Takeda Group has rights to commercialize
ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are
funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan
where the Takeda Group is solely responsible for development costs.
About Cutaneous T-Cell Lymphoma
Mycosis fungoides is the most common subtype of CTCL. CTCLs constitute a group
of non-Hodgkin lymphomas (NHLs) and are cancers of the T lymphocytes (a type
of white blood cell) that mainly affect the skin but can also involve the
blood, lymph nodes and/or internal organs in patients with advanced disease.
According to the Cutaneous Lymphoma Foundation, CTCL is the most common type
of cutaneous lymphoma and typically presents with red, scaly patches or
thickened plaques of skin that often mimic eczema or chronic dermatitis.
Progression from limited skin involvement is variable and may be accompanied
by tumor formation, ulceration and exfoliation, complicated by itching and
infections. Advanced stages are defined by involvement of lymph nodes,
peripheral blood and internal organs. According to published literature, up to
50 percent of CTCL patients’ lesions express CD30.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and
commercialization of monoclonal antibody-based therapies for the treatment of
cancer. The FDA granted accelerated approval of ADCETRIS in August 2011 for
two indications. ADCETRIS is being developed in collaboration with Millennium:
The Takeda Oncology Company. In addition, Seattle Genetics has three other
clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics
has collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Abbott, Agensys (an
affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo,
Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC
co-development agreements with Agensys and Genmab. More information can be
found at www.seattlegenetics.com.
U.S. Important Safety Information
Progressive multifocal leukoencephalopathy (PML): JC virus infection resulting
in PML and death can occur in patients receiving ADCETRIS.
Concomitant use of ADCETRIS and bleomycin is contraindicated due to pulmonary
Warnings and Precautions:
*Peripheral neuropathy: ADCETRIS treatment causes a peripheral neuropathy
that is predominantly sensory. Cases of peripheral motor neuropathy have
also been reported. ADCETRIS-induced peripheral neuropathy is cumulative.
Treating physicians should monitor patients for symptoms of neuropathy,
such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning
sensation, neuropathic pain or weakness and institute dose modifications
*Infusion reactions: Infusion-related reactions, including anaphylaxis,
have occurred with ADCETRIS. Monitor patients during infusion. If an
infusion reaction occurs, the infusion should be interrupted and
appropriate medical management instituted. If anaphylaxis occurs, the
infusion should be immediately and permanently discontinued and
appropriate medical management instituted.
*Neutropenia: Monitor complete blood counts prior to each dose of ADCETRIS
and consider more frequent monitoring for patients with Grade 3 or 4
neutropenia. If Grade 3 or 4 neutropenia develops, manage by dose delays,
reductions or discontinuation. Prolonged (≥1 week) severe neutropenia can
occur with ADCETRIS.
*Tumor lysis syndrome: Patients with rapidly proliferating tumor and high
tumor burden are at risk of tumor lysis syndrome and these patients should
be monitored closely and appropriate measures taken.
*Progressive multifocal leukoencephalopathy (PML): JC virus infection
resulting in PML and death has been reported in ADCETRIS-treated patients.
In addition to ADCETRIS therapy, other possible contributory factors
include prior therapies and underlying disease that may cause
immunosuppression. Consider the diagnosis of PML in any patient presenting
with new-onset signs and symptoms of central nervous system abnormalities.
Evaluation of PML includes, but is not limited to, consultation with a
neurologist, brain MRI, and lumbar puncture or brain biopsy. Hold ADCETRIS
if PML is suspected and discontinue ADCETRIS if PML is confirmed.
*Stevens-Johnson syndrome: Stevens-Johnson syndrome has been reported with
ADCETRIS. If Stevens-Johnson syndrome occurs, discontinue ADCETRIS and
administer appropriate medical therapy.
*Use in pregnancy: Fetal harm can occur. Pregnant women should be advised
of the potential hazard to the fetus.
ADCETRIS was studied as monotherapy in 160 patients in two phase 2 trials.
Across both trials, the most common adverse reactions (≥20%), regardless of
causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea,
anemia, upper respiratory tract infection, diarrhea, pyrexia, rash,
thrombocytopenia, cough and vomiting.
Patients who are receiving strong CYP3A4 inhibitors concomitantly with
ADCETRIS should be closely monitored for adverse reactions.
For additional important safety information, including Boxed WARNING, please
see the full U.S. prescribing information for ADCETRIS at
www.seattlegenetics.com or www.ADCETRIS.com.
Certain of the statements made in this press release are forward looking, such
as those, among others, relating to our belief that there exists clinical
evidence for pursuing the approval of ADCETRIS for CTCL. Actual results or
developments may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a difference include
risks that data resulting from the ALCANZA trial with ADCETRIS will not
support approvals in any of the studied indications. More information about
the risks and uncertainties faced by Seattle Genetics is contained in the
company’s 10-Q for the quarter ended September 30, 2012 filed with the
Securities and Exchange Commission. Seattle Genetics disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
Tricia Larson, 425-527-4180
Press spacebar to pause and continue. Press esc to stop.